Tariffs/Trade
New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports
News detail
Smaller and midsize companies say they lack the scale and financial flexibility of larger drugmakers to cut prices or reshore production, while carveouts for orphan drugs and cell and gene therapies may soften the impact for some.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.